While first-line therapy predominantly involves CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens, the prognosis for the majority of peripheral T-cell lymphoma (PTCL) subtypes remains unfavorable, except for ALK-positive anaplastic large cell lymphoma. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.